Conestat alfa
Showing 1 - 25 of 1,368
Acute Ischemic Stroke, Acute Renal Injury Trial in Basel (Conestat alfa (Ruconest®), NaCl 0.9%))
Recruiting
- Acute Ischemic Stroke
- Acute Renal Injury
- Conestat alfa (Ruconest®)
- NaCl 0.9%)
-
Basel, SwitzerlandUniversity Hospital Basel, Division of Internal Medicine
Mar 16, 2022
Coronavirus Infections Trial in Brazil, Mexico, Switzerland (Conestat alfa)
Terminated
- Coronavirus Infections
- Conestat alfa
-
São Paulo, Brazil
- +4 more
Nov 1, 2021
Non-ST Elevation Myocardial Infarction (NSTEMI) Trial in Switzerland (conestat alfa or )
Recruiting
- Non-ST Elevation Myocardial Infarction (NSTEMI)
- conestat alfa or placebo
-
Basel, Switzerland
- +3 more
May 27, 2021
Acute Kidney Injury Trial in Basel (Conestat alfa, Sodium chloride 0.9%)
Completed
- Acute Kidney Injury
- Conestat alfa
- Sodium chloride 0.9%
-
Basel, BS, SwitzerlandUniversity Hospital Basel
Aug 7, 2018
Hypophosphatasia Trial in Worldwide (ALXN1850, asfotase alfa)
Not yet recruiting
- Hypophosphatasia
- ALXN1850
- asfotase alfa
-
Hartford, Connecticut
- +29 more
Oct 6, 2023
Hypophosphatasia Trial in Würzburg (Ilofotase Alfa, 0.8 mg/kg, Ilofotase Alfa, 3.2 mg/kg)
Recruiting
- Hypophosphatasia
- Ilofotase Alfa, 0.8 mg/kg
- Ilofotase Alfa, 3.2 mg/kg
-
Würzburg, GermanyOsteologie / Klinische Studieneinheit, Orthopädische Klinik - KL
May 26, 2023
Outcomes in Hospitalised Patients Treated With Ondexxya
Not yet recruiting
- Hemorrhage
- Andexanet alfa
- (no location specified)
Jun 12, 2023
Urgent Surgery Trial (Andexanet alfa, Usual Care)
Not yet recruiting
- Urgent Surgery
- Andexanet alfa
- Usual Care
- (no location specified)
Jun 21, 2023
Efanesoctocog Alfa on Long-term Joint Health in Hemophilia A
Not yet recruiting
- Hemophilia A
- Efanesoctocog Alfa BIVV001
- (no location specified)
Jun 19, 2023
Glycogen Storage Disease Type II Pompe Disease Trial in Worldwide (GZ402666)
Completed
- Glycogen Storage Disease Type II Pompe Disease
-
Phoenix, Arizona
- +16 more
Dec 14, 2022
Multiple Myeloma Trial in Worldwide (Modakafusp alfa, Lenalidomide, Bortezomib)
Recruiting
- Multiple Myeloma
- Modakafusp alfa
- +5 more
-
Little Rock, Arkansas
- +53 more
Jan 12, 2023
Anemia Trial in Anyang-si (Ferric Derisomaltose Injection, Darbepoetin Alfa Injection)
Recruiting
- Anemia
- Ferric Derisomaltose Injection
- Darbepoetin Alfa Injection
-
Anyang-si, Korea, Republic ofHallym University Medical Center
Mar 13, 2023
Glycogen Storage Disease Type II-Pompe's Disease Trial in Worldwide (Avalglucosidase alfa (GZ402666), Alglucosidase alfa
Active, not recruiting
- Glycogen Storage Disease Type II-Pompe's Disease
- Avalglucosidase alfa (GZ402666)
- Alglucosidase alfa (GZ419829)
-
Valhalla, New York
- +9 more
May 3, 2022
Damoctocog Alfa Pegol, How it is Used in Every Day Practice, and
Not yet recruiting
- Hemophilia A
- No intervention
-
Sacramento, California
- +2 more
Jan 10, 2023
Cognitive Remote Assessment Using FLAME (CRA-FLAME)
Enrolling by invitation
- Cognitive Impairment
- Remote cognitive testing
-
Barcelona, SpainBarcelonaBeta Brain Research Center
Nov 17, 2022
Glycogen Storage Disease Type II Trial in Worldwide (Alglucosidase alfa GZ419829)
Recruiting
- Glycogen Storage Disease Type II
- Alglucosidase alfa GZ419829
-
Leuven, Belgium
- +8 more
Jan 17, 2023
Turoctocog Alfa in Haemophilic Italian Patients: Protection and
Enrolling by invitation
- Haemophilia A
- Turoctocog alfa
-
Milano, MI, Italy
- +9 more
Jan 12, 2023
Adult and Pediatric Acid Sphingomyelinase Deficiency on Early
Recruiting
- Acid Sphingomyelinase Deficiency (ASMD)
- Olipudase alfa
-
France, FranceInvestigational site number France
Jun 13, 2022
Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma Trial in Canada, Ireland, United
Active, not recruiting
- Metastatic Cutaneous Melanoma
- +15 more
- Ipilimumab
- +3 more
-
Birmingham, Alabama
- +582 more
Jan 28, 2023
Acute Graft-versus-host Disease Trial in United States (Efmarodocokin Alfa)
Active, not recruiting
- Acute Graft-versus-host Disease
- Efmarodocokin Alfa
-
Duarte, California
- +7 more
Dec 6, 2022